Valbenazine (Ingrezza) for tardive dyskinesia.
出版信息
Med Lett Drugs Ther. 2017 May 22;59(1521):83-84.
PMID:28520698
Abstract
摘要
相似文献
1
Valbenazine (Ingrezza) for tardive dyskinesia.用于迟发性运动障碍的氘代丁苯那嗪（Ingrezza）
Med Lett Drugs Ther. 2017 May 22;59(1521):83-84.
2
Valbenazine for the treatment of tardive dyskinesia.用于治疗迟发性运动障碍的氘代丁苯那嗪
Drugs Today (Barc). 2016 Dec;52(12):665-672. doi: 10.1358/dot.2016.52.12.2570977.
3
Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.苯丁胺作为首个也是唯一获批用于治疗成人迟发性运动障碍的药物。
Expert Rev Clin Pharmacol. 2018 Mar;11(3):209-217. doi: 10.1080/17512433.2018.1429264. Epub 2018 Jan 23.
4
Valbenazine-induced parkinsonism.缬苯那嗪诱发的帕金森综合征。
Parkinsonism Relat Disord. 2020 Jan;70:13-14. doi: 10.1016/j.parkreldis.2019.11.021. Epub 2019 Nov 25.
5
Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia.高效试验设计——FDA批准用于迟发性运动障碍的缬苯那嗪
N Engl J Med. 2017 Jun 29;376(26):2503-2506. doi: 10.1056/NEJMp1704898. Epub 2017 May 10.
6
Valbenazine for Tardive Dyskinesia.用于迟发性运动障碍的氘代丁苯那嗪
Clin Schizophr Relat Psychoses. 2017 Summer;11(2):113-119. doi: 10.3371/CSRP.OFGR.071717.
7
Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?比较囊泡单胺转运体 2（VMAT2）抑制剂瓦伦扎嗪和右苯丙胺治疗迟发性运动障碍的药理作用机制：一种是否优于另一种？
CNS Spectr. 2018 Aug;23(4):239-247. doi: 10.1017/S1092852918001219.
8
Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.用丁苯那嗪或缬苯那嗪治疗迟发性运动障碍：一项系统评价
J Comp Eff Res. 2018 Feb;7(2):135-148. doi: 10.2217/cer-2017-0065. Epub 2017 Oct 2.
9
Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia.氘代丁苯那嗪（阿速得）用于治疗亨廷顿舞蹈病和迟发性运动障碍。
Med Lett Drugs Ther. 2018 Apr 23;60(1545):65-68.
10
Valbenazine: First Global Approval.苯丁酸钠：全球首次获批。
Drugs. 2017 Jul;77(10):1123-1129. doi: 10.1007/s40265-017-0770-9.
Zotero 插件